| ISSN |
2220-6124 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Urology & Nephrology |
| Manuscript Type |
Review |
| Article Title |
Kidney involvement and anemia in COVID-19 infection
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Guido Gembillo, Luigi Peritore, Giuseppe Spadaro, Felicia Cuzzola, Michela Calderone, Rossella Messina, Simona Di Piazza, Flavia Sudano, Maria Elsa Gambuzza, Maria Princiotto, Luca Soraci and Domenico Santoro |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Guido Gembillo, Unit of Nephrology and Dialysis, AOU "G. Martino", University of Messina, Via Consolare Valeria n 1, Messina 98125, Sicilia, Italy. ggembillo@gmail.com |
| Key Words |
COVID 19; Hemodialysis; Renal transplant; Erythropoietin; Peritoneal dialysis; Iron deficiency; Renal anemia; Systemic inflammation; Renal replacement therapy |
| Core Tip |
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus, the causative agent of coronavirus disease-2019 (COVID-19) infection, has had a major impact worldwide. People with chronic kidney disease (CKD) and COVID-19 have an increased risk of mortality and hospitalization, with anemia, which is common in CKD, exacerbating outcomes. Patients with CKD show resistance to erythropoietin (EPO)-stimulating agents and require higher doses even after infection. Anemia in CKD is exacerbated by factors such as decreased EPO production, red blood cell fragmentation, iron or folic acid deficiency, platelet dysfunction and excessive hepcidin synthesis. These factors contribute to poor iron regulation, which further complicates anemia in COVID-19 patients. |
| Publish Date |
2025-09-17 08:57 |
| Citation |
<p>Gembillo G, Peritore L, Spadaro G, Cuzzola F, Calderone M, Messina R, Di Piazza S, Sudano F, Gambuzza ME, Princiotto M, Soraci L, Santoro D. Kidney involvement and anemia in COVID-19 infection. <i>World J Nephrol</i> 2025; 14(3): 107582</p> |
| URL |
https://www.wjgnet.com/2220-6124/full/v14/i3/107582.htm |
| DOI |
https://dx.doi.org/10.5527/wjn.v14.i3.107582 |
